The QualityStocks Daily Thursday, May 3rd, 2018

Today's Top 3 Investment Newsletters

MarketClub Analysis (VVPR) +225.19%

StockMarketWatch (IMTE) +46.29%

QualityStocks (VYCO) +42.33%

The QualityStocks Daily Stock List

Endonovo Therapeutics, Inc. (ENDV)

SeeThruEquityResearch, DSR News, Planet Penny Stocks, SecretStockPromo, StockOnion, BestDamnPennyStocks, Penny Picks, Buzz Stocks, Damn Good Penny Picks, Penny Pick Finders, Innovative Marketing, HEROSTOCKS, Stock Brain, SmallCapVoice, PennyStockProphet, Penny Stock Newsletter, PHUB News, Stock Commander, TheNextBigTrade, PREPUMP STOCKS, and OTC Markets Group reported on Endonovo Therapeutics, Inc. (ENDV), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Endonovo Therapeutics, Inc. is a biotechnology company based in Woodland Hills, California. It is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver employing its proprietary Immunotronics™ platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells. Endonovo Therapeutics is centering its efforts on inflammatory conditions in vital organs.

The Company’s Immunotronics™ platform is a non-invasive, non-implantable, bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death, and the promotion of regeneration. Its Cytotronics™ platform provides for a method of expanding and manipulating cells utilizing simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.

The basis for Endonovo’s TVEMF technology was created at NASA in combination with the development of cell therapies to treat injuries and diseases that astronauts might encounter during long term manned missions in space. The purpose of the Company’s Cytotronics™ platform is to create optimized cell-based therapies with more therapeutic potential than the un-modulated cells presently being used in regenerative medicine.

Endonovo Therapeutics is in the pre-clinical phase of evaluating its proprietary Immunotronic technology in the treatment of chronic and acute inflammatory conditions in the liver. This includes fulminant liver failure.

The Company is developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord. Endonovo is expanding its liver disease research program and its Cytotronics™ platform to create a high-fidelity drug development and toxicology testing platform.

Endonovo Therapeutics is starting a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the treatment of critical limb ischemia (CLI). This pre-clinical study will evaluate the effect of the Company’s non-invasive electroceutical technology on limb function, ischemia damage, as well as blood flow. This includes the formation of new blood vessels (angiogenesis).

Moreover, Endonovo is starting a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation in Non-Alcoholic Steatohepatitis (NASH). In addition, it is starting a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease.

Recently, Endonovo Therapeutics reported that it completed a study to evaluate the potential efficacy of its Immunotronics™ platform in a well-established preclinical model of heart failure (post-MI remodeling). With these positive results, Endonovo continues to advance the development of its pipeline of non-invasive electroceuticals targeting vascular diseases and inflammatory conditions in vital organs.

The recently completed study investigated the therapeutic efficacy of the  Immunotronics™ platform in an extensively used mouse model of heart failure (post-MI remodeling). In the model, treatment with Endonovo’s non-invasive electroceutical two or three times per day resulted in considerably increased cardiac function and reduced ventricular remodeling.

Endonovo Therapeutics, Inc. (ENDV), closed Thursday's trading session at $0.035, up 10.41%, on 1,066,585 volume with 49 trades. The average volume for the last 60 days is 1,069,886 and the stock's 52-week low/high is $0.0161/$0.125.

chart

Destiny Media Technologies, Inc. (DSNY)

Wall Street Resources, Greenbackers, SmallCapVoice, Bullseyestox, Stockhouse, Blaque Capital Stocks, Breaking Bulls, and OTC Picks reported earlier on Destiny Media Technologies, Inc. (DSNY), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Destiny Media Technologies, Inc. provides services that enable content owners to securely display and distribute their audio and video content digitally via the internet. The Company’s two major services are Play MPE® and Clipstream®. It has granted patents for secure distribution and watermarking and a pending patent for cross platform PC and mobile streaming. Destiny Media Technologies is based in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

Play MPE® provides a standardized method to securely and cost effectively distribute pre-release music to radio stations and other music industry professionals, before it is ready for sale. Clipstream® is a video format that plays on any modern smart phone, tablet, internet, TV, or computer.

Destiny Media Technologies’ revenue and earnings growth has been propelled by the flagship Play MPE® system. The Play MPE® system is being embraced by the music industry as the standard for securely moving their pre-release music to radio stations and other recipients.

  The Company has launched the next generation of the player used in the Clipstream® hosting and reporting service. This version contains the first approach in the industry utilizing the graphics processing unit of different devices to enhance the presentation of video within the browser using a browser technology named WebGL.

This new player can access resources unavailable to conventional technologies to upscale and enhance the video, improving the viewer experience. Initially designed for use in 3D rendering and game development, WebGL is a low-level 3D graphics API.  It gives the Clipstream player access to strong additional resources for enhancing and presenting video. In addition, the new player includes several other fixes and performance enhancements. In late November, Destiny Media Technologies announced a change to its strategy. The Company said that effective immediately, Clipstream® business and technical development will be transitioned to maintenance and support only.

Presently, Destiny believes Clipstream® requires a considerable investment to continue to develop as a technology and as a business. As a result, the Company is reviewing strategic alternatives to capture the value of Clipstream®, its surrounding intellectual property (IP) and business, for its shareholders. Destiny Media Technologies will focus its resources on worldwide expansion of Play MPE®. The Play MPE® business currently produces 99 percent of Company revenues.

For the fiscal 2017 year ended August 31, 2017, Destiny Media Technologies’ revenue increased in all geographic territories for a total increase of roughly 3 percent to $3,445,014. This, combined with an 11 percent decrease in overall expenditures (to $3,170,580), resulted in eliminating the prior year’s net loss increasing to net income of $288,781.

Destiny Media Technologies, Inc. (DSNY), closed Thursday's trading session at $0.1855, up 6.00%, on 15,000 volume with 4 trades. The average volume for the last 60 days is 15,941 and the stock's 52-week low/high is $0.15/$0.28.

chart

Nippon Dragon Resources, Inc. (RCCMF)

InvestorPlace, OTC Markets Group, and Streetwise Reports reported earlier on Nippon Dragon Resources, Inc. (RCCMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nippon Dragon Resources, Inc. is a hybrid mining & technology company. It has high potential and advanced stage mining assets combined with an innovative and exclusive green mining method. The Company is active in the exploration and development of gold resources in the Province of Quebec.

The Company previously went by the name Rocmec Mining, Inc. It changed its name to Nippon Dragon Resources, Inc. in April of 2014. OTCQB-listed, Nippon Dragon Resources is based in Brossard, Quebec.

The Company’s flagship gold property is Rocmec 1. This is a fully permitted project in Quebec. The project includes a 100-meter deep, two-compartment shaft, and an 844 meters’ decline, allowing access to four levels (50, 90, 110 and 130 meters).

In addition, Nippon Dragon Resources has its Courville-Maruska exploration property in Courville Township, approximately 32 kilometers’ northeast of Val-d'Or, Quebec. The property consists of 20 mining claims covering an area of about 800 hectares. The property is on a gold-bearing quartz vein system.

Nippon Dragon also has its Denain Project. This project encompasses two contiguous mining properties (Venpar and Vauquelin) totaling 24 mining titles. The Denain Project is approximately 60 km east of Val d'Or, Quebec.

The Company has its Thermal Fragmentation mining method. This is a mining method that utilizes heat to 'spall' high-grade veins, substantially reducing the use of explosives. The method only extracts the mineralized ore with minimal dilution. The extraction process allows thermal fragmentation with an accuracy of 2 cm to quickly extract any kind of hard rock up to 110 cm wide.

With this precision, high grade precious and base metal veins can undergo extraction without dilution. The thermal unit can be set up to extract a specific corridor. Thermal Fragmentation could be used as a stand-alone method or as a premier complement to any conventional hard rock mining operation.

Nippon Dragon Resources has a strategic partnership agreement with Val d’Or Resources (VOR). The partnership agreement will enhance Nippon Dragon’s position as an industry leader with its exclusive and patented Thermal Fragmentation technology.

Through the creation of a new entity, Rocmec Gold, Inc., the new partnership is expected to considerably expand Nippon Dragon’s reach within Canada and other vital markets.

Nippon Dragon Resources’ growth strategy involves the development of its gold deposits with the goal of producing revenue from its operations. Its growth strategy also involves increasing the value of its mining assets through prioritizing the exploration targets. Moreover, the Company’s growth strategy involves the commercialization and employment of its thermal fragmentation technology.

Nippon Dragon Resources, Inc. (RCCMF), closed Thursday's trading session at $0.026, down 34.01%, on 17,510 volume with 5 trades. The average volume for the last 60 days is 22,036 and the stock's 52-week low/high is $0.022/$0.06.

chart

Vycor Medical, Inc. (VYCO)

PennyStockScholar, FeedBlitz, OTCtipReporter, and Wall Street Resources reported earlier on Vycor Medical, Inc. (VYCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vycor Medical, Inc. is a provider of distinct and first-class surgical and therapeutic solutions. The Company operates two business units - Vycor Medical and NovaVision. Both of these business units adopt a minimally or non-invasive approach. Vycor Medical has U.S. Food and Drug Administration (FDA) 510(k) clearance for brain and spine surgeries and regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, Japan, Russia, and Taiwan. Vycor Medical is based in Boca Raton, Florida.

The Company’s NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight because of stroke or brain injury. The NovaVision business unit develops and provides science-driven neurostimulation therapy and other medical technologies. This helps improve and partially restore sight in patients with neurological vision impairments.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices. These have the potential for quicker, safer, and also more economical brain surgeries, as well as faster patient discharge.

The design of VBAS is to optimize neurosurgical site access and reduce patient risk. In addition, the design of VBAS is to expedite recovery and add tangible value to the professional medical community.

The Company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the United States targeted at the restoration of vision for neurologically induced vision loss.

Vycor Medical has developed NeuroEyeCoach™. This is a therapy that is highly complementary to VRT™. NeuroEyeCoach™ is a compensation therapy registered in the United States as a Class I 510(k) exempt device. The design of NeuroEyeCoach is to improve a patient's ability to scan their environment more efficiently. NeuroEyeCoach is NovaVision's eye movement compensation therapy for patients who have suffered a cerebral visual field disorder due to a stroke or brain injury.

In August, Vycor Medical reported financial results for the three and six months ended June 30, 2017. The Company’s Revenues for the six months ended June 30, 2017 were $736,000 versus $779,000 for the same period the year prior. Cash Operating Loss was $235,000, versus $329,000 for the same period in 2016. This represents a reduction of 29 percent. Operating Loss was $654,000, versus $806,000. This represents a reduction of 19 percent.

During the period, the US patent office (USPTO) issued/allowed four patents. These are all directed to the integration of neuro-navigation systems with Vycor Medical's VBAS retractor system.

The patents complement and strengthen the Company’s existing patent portfolio. This is especially in relation to Vycor’s continuing emphasis to more fully integrate its VBAS product range with neuro-navigation systems without sacrificing the surgeon's ability to visually inspect the surrounding tissue as the devices undergo insertion.

Vycor Medical, Inc. (VYCO), closed Thursday's trading session at $0.4099, up 42.33%, on 3,500 volume with 5 trades. The average volume for the last 60 days is 5,213 and the stock's 52-week low/high is $0.123/$0.596.

chart

Wealth Minerals Ltd. (WMLLF)

TradingView, MarketWatch, and InvestorsHub reported on Wealth Minerals Ltd. (WMLLF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Wealth Minerals Ltd. is a mineral resource company headquartered in Vancouver, British Columbia. It has interests in Canada, Mexico, Peru and Chile. The Company’s main emphasis is the acquisition of Lithium projects in South America. This includes interests in the Maricunga Salar in Chile. To date, Wealth Minerals has positioned itself to develop the Aguas Calientes Norte, Pujsa and Quisquiro Salars in Chile (the Trinity Project), and to work alongside existing producers in the prolific Atacama Salar. Wealth Minerals’ shares trade on the OTCQB.

The Company also maintains a portfolio of precious and base metal exploration-stage projects. This portfolio includes the 100 percent Wealth Minerals-owned Coronado property in southern Chihuahua, Mexico that spans 9911 Ha. The portfolio also includes Yanamina (Peru) and Valsequillo (Mexico).

Wealth Minerals announced in November 2016 that its wholly-owned Chilean subsidiary (Wealth Chile) entered into a formal option agreement with Atacama Lithium SpA, where it has been given the exclusive right and option to acquire a 100 percent royalty-free interest in 144 exploration concessions referred to as the Proyecto Atacama Lithium project in the Atacama Salar in Region II of Antofagasta, northern Chile.

The Company’s Wealth Chile entered into a Letter of Intent (LOI) dated December 12, 2016 with arm’s length vendors. As a result, it was given the exclusive right and option to acquire a 100 percent royalty-free interest in the mining concessions referred to as the Laguna Verde project. The Project consists of 23 Concessions for a total of 2,438 hectares. It is in Region III (Atacama), northern Chile.

The Company earlier signed a Letter of Intent (LOI) with Atacama Lithium Chile SpA concerning the grant of an option to acquire additional exploration mining concessions with an aggregate area of roughly 6,300 hectares surrounding the Laguna Verde Project and consisting of the Salar Green and Union projects.

Wealth Minerals also executed a binding letter agreement, where it or a Chilean subsidiary of Wealth was granted the option and right to acquire 49 percent of the issued and outstanding shares of San Antonio Sociedad Contractual Minera and a 24.5 percent beneficial interest in certain exploration and exploitation mining concessions, which comprise the Salares 7 Lithium project (the Seven Salars Project). The Property is a lithium brine asset portfolio currently owned 50 percent by Talison Lithium Ltd. and 50 percent by San Antonio. It has a total area of 39,400 hectares located over seven salars in Region II, northern Chile.

Earlier this month, Wealth Minerals reported that it began drilling at the Laguna Verde lithium project. Drilling at Laguna Verde is part of a more wide-ranging evaluation program that is continuing at the Laguna Verde, Atacama and Trinity projects.

The Company earlier completed Transient Electromagnetic (TEM) and Gravity surveys at Laguna Verde, the results of which were positive. This prompted Wealth Minerals to acquire the additional 6,300 hectares of property at Laguna Verde for a total of 8,700 hectares.

Wealth Minerals also reported this month that it received positive results from geophysical surveys at the Atacama project. Magneto-Telluric (MT) and coincident loop TEM surveys identified very highly conductive zones. These are interpreted to represent porous media with high-salinity fluids (potentially lithium-bearing brines) at depth.

The results provide Wealth Minerals with near-surface and deeper drill targets. Initial drill testing of shallow targets is planned for Q1 2018.

Wealth Minerals Ltd. (WMLLF), closed Thursday's trading session at $0.976, up 2.74%, on 81,902 volume with 49 trades. The average volume for the last 60 days is 92,463 and the stock's 52-week low/high is $0.92/$1.8451.

chart

alpha-En Corp. (ALPE)

Real Pennies and Wall Street Mover reported earlier on alpha-En Corp. (ALPE), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corp. is a clean technology business with its corporate office in Yonkers, New York.  The Company concentrates on enabling next generation battery technologies through developing and bringing to market high purity lithium metal and associated products produced in an environmentally sustainable manner.  alpha-En lists on the OTC Markets’ OTCQB.

The Company’s lithium metal is purer than what is presently available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply.

alpha-En has strategic research partnerships with Argonne National Laboratory, Princeton University, and the City University of New York. These partnerships are to advance commercialization and scale-up of production.

The Company enables next generation energy storage. alpha-En’s focus is on room temperature production of high purity lithium metal and associated products. Its flexible disposition method can also streamline battery manufacturing, leading to battery production cost benefits.

The room temperature process requires minimal electricity. Furthermore, using Lithium Carbonate as feedstock reduces the Company’s raw material costs. The process is conducted at 20°-30°C.

The room temperature, proprietary, patent pending process is mercury and chlorine free. This eliminates the use and release of toxic chemicals and expensive containment costs.

alpha-En announced in December of 2017 that it filed, via its subsidiary CLC, a number of patent applications, which relate to and claim high purity lithium and associated products and the process of making same. This further strengthens the core Intellectual Property (IP) of the Company that has already filed numerous patents around its proprietary technology.

This past February, alpha-En announced the closing of a tranche of its Ser A preferred shares in the amount of $ 1.950.000. The round was led by the Pitroda Group LLC and three members of the Management team.

Mr. Jerome Feldman, Executive Chairman, said, "We are very excited to have earned Sam's endorsement of our process and its potential in the marketplace, not only as our CEO but now also as a significant investor. Management, current shareholders and new investors continue to showcase their commitment to the Company's future by increasing their capital contributions, which allows us to continue to execute against our vision. For that we are very grateful."

alpha-En Corp. (ALPE), closed Thursday's trading session at $2.00, even for the day. The average volume for the last 60 days is 3,261 and the stock's 52-week low/high is $1.19/$4.35.

chart

Altamira Gold Corp. (EQTRF)

Junior Mining Network, Barchart, InvestorX, Stockwatch, MarketWatch, Stockhouse, Capital Equity Review, Spotlight Growth, 4-Traders, StreetWise Reports, WalletInvestor, and Stockscores reported on Altamira Gold Corp. (EQTRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 1994, Altamira Gold Corp. engages in the acquisition, exploration, development, and mining of mineral properties in Canada and Brazil. A junior natural resource enterprise, the Company previously went by the name Equitas Resources Corp. It changed its name to Altamira Gold Corp. in April of 2017. OTCQB-listed, Altamira Gold has its corporate headquarters in Vancouver, British Columbia.

Altamira Gold is focusing on the exploration and development of gold deposits within the Juruena belt of western Brazil. The Company has a Brazil focus. It has 12 license areas consisting of 200,000-plus ha in the prolific Juruena gold belt (7–10M oz of artisanal gold production).

Furthermore, the Company has its advanced Cajueiro Project. This project has an NI 43- 101 (National Instrument 43-101) resource of Indicated Resources of 214,000 oz Au and Inferred Resources of 204,000 oz Au plus an additional 79,000 oz at 1.61 g/t Au in oxides (as Saprolite).

Last year, two new zones were discovered at the Cajueiro Project. The two new zones discovered are at Baldo East and Toninho - 6m @ 21.7 g/t in trench 20 and @5.53 g/t in trench 25.

Altamira Gold also has its Crepori Project. This Project is 8,323 ha with historical small scale production. The Crepori Project is 105 km SSW of Eldorado Gold’s TZ Project. Surface sampling at Crepori has returned values up to 1022.98 g/t gold with roughly 10 percent of surface samples returning +5 g/t gold.

This past February, Altamira Gold reported that it started an exploration program for concealed porphyry copper mineralization throughout the Juruena Belt of Mato Grosso state in eastern Brazil. The Company’s concession areas within the belt, which include Cajueiro, Apiacás, Santa Helena and Carlinda, are totally surrounded by third party claims. A number of major mining companies, including Anglo American Corp., Nexa Resources S.A. and Vale S.A., have all recently staked large areas of the Juruena gold belt amounting to roughly 3.5M hectares.

Recently, Altamira Gold reported that it claimed substantial additional ground within the Juruena belt in Mato Grosso, Brazil. The new claims total 52,378 hectares. These claims have increased Altamira’s strategic land positioning to more than 200,000 hectares in the Juruena Belt.

Today, Altamira Gold announced that more trenching began on April 26, 2018 within the Baldo East target area at the Cajueiro project in western Brazil. The trench program will comprise a minimum of 1000 meters. The design of this program is to further extend the strike of several high-grade east-west trending mineralized structures in the Baldo East target area of the Cajueiro project.

Altamira Gold Corp. (EQTRF), closed Thursday's trading session at $0.138, up 16.46%, on 33,000 volume with 9 trades. The average volume for the last 60 days is 21,606 and the stock's 52-week low/high is $0.1136/$0.288.

chart

MOJO Organics, Inc. (MOJO)

InvestorsHub and Business Insider reported on MOJO Organics, Inc. (MOJO), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

MOJO Organics, Inc. engages in the product development, production, marketing, and distribution of beverages. The Company’s beverages are Non GMO (Non-Genetically Modified) Project Verified. Its products include coconut water, sparkling coconut water, as well as tropical juice. Incorporated in 2007, MOJO Organics lists on the OTC Markets Group’s OTCQB. The Company has its head office in Jersey City, New Jersey.

Non GMO Project Verified is the highest certification. MOJO beverages have zero added sugar, no preservatives and low sodium. In addition, MOJO is vegan and gluten free.

MOJO coconut water comes in four flavors. These are regular coconut water, pineapple juice, passion fruit juice, and mango juice.

The Company’s sparkling coconut water comes in the same four flavors. MOJO Pure Coconut Water has been ranked in the top five brands of coconut water on Amazon.

MOJO Organics’ tropical juice comes in three flavors. These are mangosteen juice, dragon fruit juice, as well as pomel juice.

In February, MOJO Organics reported its Q4 2017 results. Sales Revenue for the three months ended December 31, 2017 was $289,124, a $132,339 increase (84 percent) over the same period the year prior of $156,786.

Gross Profit was $124,872. This represents an increase of $26,731 from the same period the year prior. The Net Loss for the period decreased by $252,668 to $187,463. This represents a 57 percent improvement from Q4 2016.

Mr. Glenn Simpson, MOJO Organics’ Chairman and Chief Executive Officer, said “As demonstrated by our significant revenue growth we made great progress in increasing same store sales and the number of retail points of sale in the eastern United States, during the quarter."

During Q4 2017, MOJO Organics considerably increased its ecommerce business on Amazon.  Revenue was up by 149 percent to $39,871. This represents an increase of $23,828 versus the same quarter last year of $16,042.

MOJO Organics, Inc. (MOJO), closed Thursday's trading session at $0.17, down 15.00%, on 2,050 volume with 1 trade. The average volume for the last 60 days is 15,152 and the stock's 52-week low/high is $0.12/$3.18.

chart

Vitalibis, Inc. (VCBD)

Stockflare, Stockwatch, Stockhouse, Simply Wall St, Morningstar, InvestorsHub, TradingView, 4-Traders, Stockopedia, GuruFocus, Investors Hangout, OTC Markets, Market Exclusive, and StreetInsider reported on Vitalibis, Inc. (VCBD), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Vitalibis, Inc. is a technology based seller of premium, full spectrum phyto-cannabinoid rich (PCR) products. The Company is also a seller of personal care and organic certified nutritional products formulated with premium hemp extracts. Vitalibis is working to be an iconic lifestyle brand that promotes health and wellness within the fast growing medicinal cannabis industry.

Established in 2017, Vitalibis has its corporate headquarters in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets’ OTCQB. Last week, Vitalibis announced that its stock started trading on the OTCQB Market after successfully uplisting from the OTC Pink Market.

Vitalibis looks to use a strong technology platform and unique micro-influencer sales model to market and sell its products. Further to taking advantage of technology and selling high-quality products, the Company’s emphasis is on supporting non-profits with environmental and neuro-emotional missions.

Vitalibis is working to sell branded, full spectrum, phyto-cannabinoid rich hemp oil products, cold processed skincare, body care and organic certified nutritional products that are effective and safe. The Company uses the EWGs Skin Deep Cosmetics Database and other scientific research findings to help guide it on what to put in its products.  All of Vitalibis’ products are made using cold-processed technology, to minimize heat and harmful ingredients.

Recently, Vitalibis announced a technology integration agreement to license the state-of-the-art newkleus™ technology to facilitate Vitalibis’ micro-influencer sales model, and enhance and complement the Company’s social media strategy. This agreement grants Vitalibis an exclusive license for the newkleus patent-pending, user-generated content (UGC) technology for all applications in the cannabis industry.

In addition, the integration of Vitalibis and newkleus technologies will considerably enhance Vitalibis’ ability to operate digital “engagement campaigns” that employ creative gamification principles and leaderboards to reward user behavior and boost user interaction.

This week, Vitalibis announced that its technology team is building a best-of-breed ecommerce platform. The Company is using the most contemporary in open-source technology, featuring Magento Enterprise Edition 2.0 as its digital ecommerce platform.

Mr. Steven Raack, Chief Executive Officer of Vitalibis, said, “Technology is at the heart of our business model for building relationships, disseminating information and connecting people. We must offer our customers and community a digital experience which is simple and engaging.  Magento is the perfect partner for us to continue to accomplish our vision for being the trusted leader in the cannabis industry.”

Vitalibis, Inc. (VCBD), closed Thursday's trading session at $1.52, even for the day, on 258 volume with 4 trades. The average volume for the last 60 days is 3,257 and the stock's 52-week low/high is $1.25/$1.60.

chart

Consumer Capital Group, Inc. (CCGN)

StockTwits, OTC Markets, Street Insider, Market Exclusive, 4-Traders, Stockhouse WalletInvestor, and Stockopedia reported on Consumer Capital Group, Inc. (CCGN), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Consumer Capital Group, Inc.’s intention is to become a foremost Financial Technology (Fintech) company, which focuses on comprehensive financial advisory services for micro, small-to-medium sized enterprises (SMEs) in the People's Republic of China. The Company, by way of its subsidiaries, provides microfinancing and financial advisory services to micro, and SMEs. It also provides financial consulting services. Consumer Capital Group has its corporate headquarters in Flushing, New York. The Company lists on the OTC Markets Group’s OTCQB.

Consumer Capital Group mainly engages in two core businesses. These are microfinancing and financial advisory service. The Company operates its direct microfinancing business via its subsidiary, Arki E-Commerce, and its VIE, Arki Network. It operates its financial advisory service via Arki Network’s wholly-owned subsidiary Yin Hang.

Acquired by Arki Network in December 2016, Yin Hang commenced its operations in 2013. Yin Hang has developed its own big data risk assessment system to provide credit rating and risk management solutions to borrowers and financial institutions.

Consumer Capital Group provides advisory and risk assessment services to lenders and borrowers to help increase the efficiency of loan origination by financial institutions. The Company provides direct loans to SMEs and sole proprietors. It also provides private loans to borrowers. In addition, the Company acts as an intermediary to facilitate the loan transactions.

Consumer Capital Group offers financial consulting services. This includes loan origination criteria checkup, risk assessment, and loan monitoring services on a third party peer to peer online lending platform to SMEs and financial institutions.

Furthermore, the Company offers wealth management services through a financial advisory platform. This platform attracts capital from investors to invest in fixed income opportunities, including inter-bank loans, currency exchange products, and other equity investment opportunities to achieve return on their investments (ROI).

Consumer Capital Group also offers asset management, management consulting, and Internet information services. Moreover, it offers advertising design, production, agent, as well as publishing services.

Consumer Capital Group, Inc. (CCGN), closed Thursday's trading session at $7.88, even for the day, on 4,123 volume with 7 trades. The average volume for the last 60 days is 4,042 and the stock's 52-week low/high is $2.50/$8.80.

chart

Generex Biotechnology Corporation (GNBT)

StreetInsider, Stockhouse, Insider Financial, MicroCap Daily, InvestorsHub, OTC Markets, and Zacks reported on Generex Biotechnology Corporation (GNBT), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Generex Biotechnology Corporation engages in the discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies. A biopharmaceutical enterprise, the Company’s principal focus has been its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator.

OTCQB-listed, Generex Biotechnology has offices in Miramar, Florida, and Burlington, Ontario. The Company is part of the Biotechnology industry in the Healthcare sector. Sometime in 2018, Generex Biotechnology will have a new name - NuGenerex Life Sciences Holdings, Inc. (NuGenerex).

Generex Biotechnology has two business focuses. One is implementing an acquisition strategy. The second is financing sponsored clinical trials.

Generex is positioning its business as a diversified holding company involved in increasing its pipeline of compounds, therapies, treatments, diagnostics, and technologies in all stages in the Food and Drug Administration (FDA) process through accretive acquisitions.

Antigen Express, Inc. is a wholly-owned subsidiary of Generex Biotechnology. Antigen Express is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Its emphasis is on stimulating critical members of the immune response, called T helper cells.

In addition, Hema Diagnostic Systems (HDS) is a subsidiary of Generex Biotechnology. HDS is a manufacturer of in-vitro medical diagnostic devices for point of care and laboratory-based tests, mainly for infectious diseases.

Generex Biotechnology’s Generex Oral-lyn is an insulin spray for the treatment of Type I and Type II diabetes. The Company states that Generex Oral-lyn is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin. It is conveniently delivered to the membranes of the oral cavity by way of a simple asthma-like device with no pulmonary (lung) deposition.

Generex Biotechnology announced in December of 2017 that its wholly-owned subsidiary, Antigen Express, Inc., entered into a License and Research Agreement with Shenzhen BioScien Pharmaceuticals Co. Ltd. to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including Taiwan, Hong Kong, and Macau).

Generex Biotechnology Corporation (GNBT), closed Thursday's trading session at $2.90, down 1.69%, on 1,474 volume with 11 trades. The average volume for the last 60 days is 914 and the stock's 52-week low/high is $2.16/$6.00.

chart

The QualityStocks Company Corner

Mr. Amazing Loans Corporation (OTCQB: MRAL)

The QualityStocks Daily Newsletter would like to spotlight Mr. Amazing Loans Corporation (MRAL).

Mr. Amazing Loans Corporation (OTCQB:MRAL) (“Mr. Amazing Loans”) announces that effective April 30, 2018, its corporate name changed from IEG Holdings Corporation to Mr. Amazing Loans Corporation. In connection with its name change, Mr. Amazing Loans’ ticker symbol changed from IEGH to MRAL. For more information about Mr. Amazing Loans, visit the new Investor Relations website at https://ir.mramazingloans.com.

Mr. Amazing Loans Corporation (OTCQB: MRAL) is a publicly traded, global leader in consumer finance providing small-sized online personal loans in the United States via a state-licensed operating subsidiary, Investment Evolution Corporation, under the consumer brand “Mr. Amazing Loans.” Based in Las Vegas, the company originates consumer loans in 20 states: Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri, Nevada, New Jersey, New Mexico, Ohio, Oregon, Pennsylvania, Texas, Utah, Virginia and Wisconsin via its online platform and distribution network. MRAL is a licensed direct lender with state licenses and/or certificates of authority to lend in each state and offers all loans within the prevailing statutory rates.

Mr. Amazing Loans is a leading FinTech company specializing in dedicated loan amounts of $5,000 to $10,000 offered directly to consumers through an easy-to-use website known for its professional interaction with applicants. All loans are originated, processed and serviced out of the company’s Las Vegas corporate offices, eliminating the need for physical locations in each state where MRAL is licensed to conduct business. The company’s loans are unsecured consumer loans that mature in five years at interest rates significantly less than those of payday lenders. Consumers are able to receive same-day processing and are assured of no hidden or additional fees, no prepayment penalty, with repayment and interest rates fixed at 29.9% or less Annual Percentage Rate (APR) for the life of the loan.

The Center for Responsible Lending states the typical payday loan has rates ranging from 391% to 521% APR on loans that typically range from $100 to $1,000. Conversely, Mr. Amazing Loans’s terms are designed with low fixed repayments to fit into consumer budgets with the added goal of helping clients reach a stronger financial position. Loan funds are deposited directly into an approved consumer’s checking account and may be approved the same day after necessary application documentation is received.

Mr. Amazing Loans Corporation has also incorporated Investment Evolution Crypto, LLC, a 100 percent owned subsidiary, and tasked the new company with exploring business opportunities in the cryptocurrency/blockchain industry. Specifically, the subsidiary company will explore the legalities and economic risks of entering into a joint venture with MRAL’s other 100 percent owned subsidiary company, Investment Evolution Corporation dba Mr. Amazing Loans. Among the questions to be answered during this development planning stage are whether Mr. Amazing Loans should accept repayment of customer loans in the form of leading crypto/blockchain currencies such as Bitcoin, provide the equivalent of USD $5,000 and $10,000 loans to consumers in cryptocurrencies, and potentially create and issue an Investment Evolution cryptocurrency.

Paul Mathieson, MRAL’s chairman and Chief Executive Officer, has over 19 years of finance industry experience in lending, funds management, stock market research and investment banking. He has been a member of the board of directors at MRAL since 2012 and of its subsidiary since 2009. Mathieson founded IEG Holdings Limited in Sydney, Australia, launching the Amazing Loans business in that country in 2005 and then in the United States in 2010. He was awarded Ernst & Young’s 2007 Australian Young Entrepreneur of the Year (Eastern Region). Mathieson is joined by Carla Cholewinski, who serves as chief operating officer with over 37 years of experience in the finance industry including banking, credit union management, regulatory oversight, debt securitization and underwriting.

Mr. Amazing Loans Corporation (MRAL), closed the day's trading session at $0.31, even for the day, on 7,985 volume with 10 trades. The average volume for the last 60 days is 204 and the stock's 52-week low/high is $0.14/$4.19.

Recent News

chart

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) ("Global") is pleased to announce that, MoneyTrac Technology, Inc. ("MTRAC", the "Company"), of which Global is a significant shareholder (currently 18% ownership), announced on Tuesday May 1st, that in an effort to sustain and support the growth of the Company's inside sales, marketing, and customer care departments located in Las Vegas, NV, the Company, through its sublease with Global Payout who is an 18% shareholder of MTRAC, has transitioned into a considerably larger and more resourceful call center location within the city of Las Vegas. Also today, CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, announced the publication of an editorial featuring GOHE, a client of CNW and a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. To view the full publication titled “Subsidiary Industries Prepare for Growing Cannabis Market,” visit: http://cnw.fm/5MuQ1.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.019, up 13.10%, on 5,360,951 volume with 242 trades. The average volume for the last 60 days is 11,714,128 and the stock's 52-week low/high is $0.0123/$0.16.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that it has signed an agreement with an international biopharmaceutical company to assess the potential of the Company's recently acquired PreEMT™ platform to develop a unique manufacturing process and improve the quality of a key protein-based drug currently under development.

Pressure BioSciences Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.35, off by 10.67%, on 6,520 volume with 11 trades. The average volume for the last 60 days is 1,440 and the stock's 52-week low/high is $0.70/$8.994.

Recent News

chart

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Cobalt exploration and development company First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) this morning announced that the results of recent drilling have doubled the strike length of the mineralized zone in the Kerr area to over 200 meters. To view the full press release, visit: http://nnw.fm/nV18c.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.612, up 6.99%, on 117,809 volume with 62 trades. The average volume for the last 60 days is 146,957 and the stock's 52-week low/high is $0.3148/$1.3041.

Recent News

chart

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF) ("Sunniva" or the “Company") is pleased to announce that it has selected the 126-acre Okanagan Falls, British Columbia site to build its Sunniva Canada Campus.  The Company’s wholly-owned subsidiary, Sunniva Medical Inc. (“SMI”), has entered into a purchase and sale agreement to acquire the entire 126-acre industrial zoned property for a purchase price of $7 million.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.85, up 0.74%, on 27,718 volume with 138 trades. The average volume for the last 60 days is 37,494 and the stock's 52-week low/high is $6.035/$16.00.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

NetworkNewsAudio announces the Audio Press Release (APR) titled "Smart Money Flowing into Lithium Market," featuring Lithium Chile Inc. (TSXV: LITH) (OTC: LTMCF). To hear the NetworkNewsAudio version, visit http://nnw.fm/BU97n. To read the original editorial, visit http://nnw.fm/lV1nC.

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.6772, even for the day. The average volume for the last 60 days is 1,958 and the stock's 52-week low/high is $0.6599/$0.9021.

Recent News

chart

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) (the “Company” or “PreveCeutical”), announces the grant of two additional permits (the “Permits”) by the Australian Government, Department of Health, for the importation of a second shipment of cannabis plant materials into Australia for research purposes and the shipment of dried cannabis materials pursuant to the Permits.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.215, off by 0.46%, on 1,160 volume with 3 trades. The average volume for the last 60 days is 22,173 and the stock's 52-week low/high is $0.01/$0.80.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

British Columbia-based cannabis cultivation firm Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) this morning announced that it has closed its acquisition of Island Green Cure Ltd. (“IGC”), an advanced-stage cannabis production license applicant under Health Canada’s Access to Cannabis for Medical Purposes Regulations. To view the full press release, visit: http://cnw.fm/0jhW2.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.6868, off by 0.67%, on 241,845 volume with 181 trades. The average volume for the last 60 days is 137,105 and the stock's 52-week low/high is $0.125/$0.8612.

Recent News

chart

Zenergy Brands, Inc. (ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

Zenergy Brands, Inc. (OTCQB: ZNGY), the nation's leading next-generation utility announced today it has elected Mr. Joshua Campbell to its Board of Directors and is also adding a new member to the executive leadership team, energy industry veteran, Mr. Chris Crabtree.

Zenergy Brands, Inc. (ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0092, off by 5.15%, on 1,120,408 volume with 27 trades. The average volume for the last 60 days is 3,018,949 and the stock's 52-week low/high is $0.0027/$0.045.

Recent News

chart

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

EVIO Inc. (OTCQB: EVIO) ("EVIO" or the "Company"), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, is pleased to announce that EVIO Canada has closed its previously announced acquisition of 50% stake in Keystone Labs Inc. Also today, EVIO announced that it had executed an asset purchase agreement to acquire 100 percent of Leaf Detective, LLC, a California-based testing laboratory (http://cnw.fm/TRaC0).

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.58, off by 3.07%, on 38,576 volume with 69 trades. The average volume for the last 60 days is 74,271 and the stock's 52-week low/high is $0.47/$2.70.

Recent News

chart

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF).

Pharmaceutical-grade cannabis company ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning issued a business update. To view the full press release, visit: http://cnw.fm/OevH5.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” ABcann Global CEO Barry Fishman said.

ABcann Global owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

ABcann has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by ABcann’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting ABcann’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

ABcann’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with ABcann’s philosophy of quality and innovation.

ABcann’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, ABcann also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

ABcann Global (ABCCF), closed the day's trading session at $1.09, off by 7.63%, on 414,777 volume with 399 trades. The average volume for the last 60 days is 318,323 and the stock's 52-week low/high is $0.6171/$3.2929.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.